Prelude Therapeutics secures $60M from Incyte option deal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. GPRK
6. SCHW
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to Prelude Therapeutics secures $60M from Incyte option deal

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

November 4, 2025 7:01 AM EST

Incyte secures an exclusive option to acquire Preludes mutant selective JAK2V617F JH2 inhibitor program

Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs)

Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sales

Prelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte... More